KALA BIO, Inc. entered into a Securities Purchase Agreement with certain institutional investors, pursuant to which the Company agreed to issue and sell 2,928 Series F Convertible Non-Redeemable Preferred Stock at an issue price of $683 per preferred share for gross proceeds of $1,999,824 on December 21, 2023. The transaction is expected to close on December 22, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.9 USD | +2.79% | -1.53% | -1.43% |
04-02 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
03-29 | KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.43% | 19.43M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding